This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (78)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Progress Report with Review of Studies Regarding Mechanism of Action

WILLIAM B. PARSONS, JR., M.D.

Arch Intern Med. 1961;107(5):639-652.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

The use of nicotinic acid in large doses has gained wide recognition as a means of reducing serum cholesterol levels without dietary restriction.^1,2 The greatest reduction occurs in the β-lipoprotein cholesterol fraction, with an increase in the ₁-lipoprotein cholesterol fraction.^3,4 Both free and esterified cholesterol fractions are reduced.⁵ Total lipids, fatty acids, and triglycerides decrease in the same manner as cholesterol.^3,5-8 Fatty acids and triglycerides are reduced.^5,6,8 Phospholipids are reduced perhaps proportionately less than other lipids.^3,5

It is well to emphasize that there is no definite evidence that reduction in serum cholesterol levels in humans will result in retardation of atherogenesis or in removal of existing atheromata. However, it seems reasonable to study any method of reducing serum cholesterol levels to determine its efficacy, its safety, and its ultimate effect on the arteries. Studies of toxicity must include not only the . . . [Full Text PDF of this Article]

Author Affiliations
MADISON, WIS.

Jackson Clinic and Foundation.

Footnotes
Submitted for publication Aug. 25, 1960.

Research grants for this study were received from the National Heart Institute (U.S. Public Health Service Grant No. H3787), American Heart Association, and Wisconsin Heart Association.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?